The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk
Open accessAbstract
Objectives To determine the relationship between non-high-density lipoprotein cholesterol (HDL-C) lowering and coronary heart disease (CHD) risk reduction for various lipid-modifying therapies.Background Non-HDL-C is the second lipid target of therapy after low-density lipoprotein cholesterol (LDL-C).Methods Randomized placebo or active-controlled trials were evaluated. The effect of mean non-HDL-C reduction on the relative risk of nonfatal myocardial infarction and CHD death was estimated using Bayesian random-effects meta-analysis models adjusted for study duration. Cochrane's Q was used to test for heterogeneity.Results Inclusion criteria were met by 14 statin (n = 100,827), 7 fibrate (n = 21,647), and 6 niacin (n = 4,445) trials, and 1 trial each of a bile acid sequestrant (n = 3,806), diet (n = 458), and ileal bypass surgery (n = 838). For statins, each 1% decrease in non-HDL-C resulted in an estimated 4.5-year CHD relative risk of 0.99 (95% Bayesian confidence interval: 0.98 to 1.00). The fibrate model did not differ from the statin model (Bayes factor K = 0.49) with no evidence of heterogeneity. The niacin model was moderately different from the statin model (K = 7.43), with heterogeneity among the trials (Q = 11.8, 5 df; p = 0.038). The only niacin monotherapy trial (n = 3,908) had a 1:1 relationship between non-HDL-C and risk reduction. No consistent relationships were apparent for the 5 small trials of niacin in combination. The 95% confidence intervals for the single trials of diet, bile acid sequestrants, and surgery also included the 1:1 relationship.Conclusions Non-HDL-C is an important target of therapy for CHD prevention. Most lipid-modifying drugs used as monotherapy have an approximately 1:1 relationship between percent non-HDL-C lowering and CHD reduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Like LDLC, non-HDLC is treatable with existing lipid-lowering agents and there is a direct, consistent relationship between the magnitude of non-HDLC lowering and cardiovascular risk reduction observed in meta-analyses and trials with statins and other lipid-lowering agents [56,57].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [56]
In the citing paper
“Non-HDL-C can provide a better risk estimation compared with LDL-C, in particular in HTG combined with diabetes, the MetS, or CKD.This is supported by a recent meta-analysis including 14 statin trials, seven fibrate trials, and six nicotinic acid trials.44”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [44]
In the citing paper
“Non-HDL cholesterol predicts CVD risk similarly to or even better than LDL cholesterol.483”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [483]
In the citing paper
“In this respect, it is relevant that a meta-analysis of the relationship between improvement of the plasma lipoprotein profile and the rate of CV events has demonstrated that non-HDL-C lowering translates into a reduction in risk independent of the mechanisms (statins, resins, diet and ileal bypass) involved. 131”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [131]
In the citing paper
“However, the meta-analysis of Robinson et al . 131 indicates that LDL-C reduction translates into CV benefits, independent of the mechanism involved.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [131]
In the citing paper
“In this respect, it is relevant that a meta-analysis of the relationship between improvement of the plasma lipoprotein profile and the rate of CV events has demonstrated that non-HDL-C lowering translates into a reduction in risk independent of the mechanisms (statins, resins, diet and ileal bypass) involved.131”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [131]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Kass, R. E., & Raftery, A. E. (1995) · Journal of the American Statistical Association · doi:10.1080/01621459.1995.10476572 · Cited by 12,558
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Flagged first, then by citations
1 of the 61 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Leren, 1966, The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction, Acta Med Scand, 466, 5
Cited by
Sorted by citations
Items 201–300 of 365
Discordant Lipid Pattern and Carotid Atherosclerotic Plaque. Importance of Remnant Cholesterol
Masson, W. M., Lobo, M., Molinero, G., & Siniawski, D. A. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170069 · Cited by 13
Langlois, M. R., Nordestgaard, B. G., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H. H. E., Borén, J., Bruckert, É., Catapano, A. L., Cobbaert, C. M., et al. (2021) · Laboratory Service · doi:10.17116/labs20211001145 · Cited by 13
Baker, W. L., & Datta, R. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0092-8 · Cited by 13
Comparison of cardiovascular disease risk associated with 3 lipid measures in Japanese adults
Takeuchi, T., Nemoto, K.-I., Takahashi, O., Urayama, K. Y., Deshpande, G. A., & Izumo, H. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.06.005 · Cited by 12
Farnier, M., Chen, E., Johnson‐Levonas, A. O., Sisk, C. M., & Mitchel, Y. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s58694 · Cited by 12
Владиславович, Е. М., & Arutyunov, G. P. (2023) · Diseases · doi:10.3390/diseases11040140 · Cited by 12
Jun, J. E., Jeong, I., Yu, J. M., Kim, S. R., Lee, I. K., Han, K. A., Choi, S. H., Kim, S., Park, H. K., Mok, J., et al. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0265 · Cited by 12
Colivicchi, F., Fusco, S. A. D., Arca, M., Leggio, M., Caldarola, P., Murrone, A., Valente, S., Urbinati, S., Roncon, L., Amodeo, V., et al. (2021) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001175 · Cited by 13
Sanz, J., Moreno, P., & Fuster, V. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.027 · Cited by 14
Lipoprotein(a) in Cardiovascular Diseases: Insight From a Bibliometric Study
Šuran, D., Vošner, H. B., Završnik, J., Kokol, P., Sinkovič, A., Kanič, V., Kokol, M., Naji, F. H., & Završnik, T. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.923797 · Cited by 14
Márk, L., Paragh, G., Karádi, I., Reiber, I., Pados, G., & Kiss, Z. (2012) · Archives of Medical Science · doi:10.5114/aoms.2012.30283 · Cited by 12
Dandapat, S., & Robinson, J. G. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-016-0621-1 · Cited by 12
Self-citationSteen, J. P., Klatt, K. C., Chang, Y., Guyatt, G. H., Zhu, H., Świerz, M. J., Storman, D., Sun, M., Zhao, Y., Ge, L., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-02229 · Cited by 11
Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part I: Alternative Niacin Regimens
Dunbar, R. L., & Goel, H. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0563-8 · Cited by 11
Rana, J. S., & Boekholdt, S. M. (2010) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32833f0365 · Cited by 11
Orringer, C. E. (2013) · Clinical Lipidology · doi:10.2217/clp.12.89 · Cited by 11
Volpe, M., Volpe, R., Gallo, G., Presta, V., Tocci, G., Folco, E., Peracino, A. P., Tremoli, E., & Trimarco, B. (2017) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-017-0211-6 · Cited by 11
Secondary prevention of cardiovascular diseases: current state of the art
Hasenfuss, G. P. (2018) · Kardiologia Polska · doi:10.5603/kp.a2018.0198 · Cited by 11
Hosseinabadi, S. M., & Nasrollahzadeh, J. (2021) · British Journal Of Nutrition · doi:10.1017/s0007114521004645 · Cited by 11
Masson, W. M., Lobo, M., Siniawski, D. A., Molinero, G., Huerin, M. S., & Nogueira, J. P. (2019) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-019-00330-8 · Cited by 10
Simprini, L. A., Villines, T. C., Rich, M. W., & Taylor, A. J. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.11.005 · Cited by 10
Bramlage, P., Lanzinger, S., Rathmann, W., Gillessen, A., Scheper, N., Schmid, S. M., Kaltheuner, M., Seufert, J., Danne, T., & Holl, R. W. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12783 · Cited by 10
Soran, H., Ho, J. H., Adam, S., & Durrington, P. N. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000614 · Cited by 10
Kónyi, A., Sárszegi, Z., Hild, G., & Gaszner, B. (2016) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2016-0003 · Cited by 13
Laboratory evaluation of lipid parameters in clinical practice
Pancholia, A. K., Kabra, N., & Gupta, R. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.02.002 · Cited by 14
Khandouzi, N., Zahedmehr, A., Asadian, S., & Nasrollahzadeh, J. (2023) · Coronary Artery Disease · doi:10.1097/mca.0000000000001259 · Cited by 9
A systematic review and meta-analysis of the prevalence of dyslipidaemia among adults in Malaysia
Mohamed-Yassin, M.-S., Rosman, N., Kamaruddin, K. N., Miptah, H. N., Baharudin, N., Ramli, A. S., Abdul-Razak, S., Lai, N. M., & GLOBALDYS Study Investigators (2023) · Scientific Reports · doi:10.1038/s41598-023-38275-7 · Cited by 10
Jacobson, T. A. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.56 · Cited by 10
Self-citationPepine, C. J., Jacobson, T. A., Carlson, D. M., Kelly, M. T., Setze, C. M., Gold, A., Stolzenbach, J. C., & Williams, L. A. (2010) · Clinical Cardiology · doi:10.1002/clc.20830 · Cited by 9
Self-citationBaruch, L., Chiong, V. J., Agarwal, S., & Gupta, B. P. (2013) · Cholesterol · doi:10.1155/2013/502948 · Cited by 9
The Importance of Non High Density Lipoprotein Cholesterol in Dyslipidaemia Management
Chowdhury, S., & Chowdhury, J. R. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000623 · Cited by 9
Богачевская, С. А., & Николаевич, Б. А. (2017) · Social Aspects of Population Health · doi:10.21045/2071-5021-2017-53-1-1 · Cited by 10
Ferdinand, K. C., Davidson, M. H., Kelly, M. T., & Setze, C. M. (2012) · American Journal of Cardiovascular Drugs · doi:10.2165/11597940-000000000-00000 · Cited by 9
Targeting Residual Risk: The Rationale for the Use of Non-HDL Cholesterol
Alla, V. M., Kaushik, M., & Mooss, A. N. (2010) · Southern Medical Journal · doi:10.1097/smj.0b013e3181d7e3a8 · Cited by 9
Koren, M. J., Jones, P. H., Robinson, J. G., SULLIVAN, D. R., Cho, L., Hucko, T., López, J. A. G., Fleishman, A. N., Somaratne, R. M., & Stroes, E. S. G. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00181-8 · Cited by 9
Self-citationNon-HDL Cholesterol and Atherosclerotic Cardiovascular Disease.
Puri, R., Mehta, V., Iyengar, S. S., Narasingan, S. N., Duell, P. B., Sattur, G. B., Vijayaraghavan, K., Mohan, J. C., Wangnoo, S. K., Dalal, J. J., et al. (2020) · PubMed · Cited by 7
Mohiuddin, S. M., Thakker, K. M., Setze, C. M., & Kelly, M. T. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.569018 · Cited by 8
Atherogenic markers in predicting cardiovascular risk and targeting residual cardiovascular risk
Catapano, A. L., Tokgözoğlu, L. S., Silva, A. M. E., & Bruckert, É. (2019) · Atherosclerosis Supplements · doi:10.1016/j.athx.2019.100001 · Cited by 8
Factores de riesgo cardiovascular
Ros, A. L., Al-Mahdi, E. A. R., Moya, R. R. M., & Gómez, J. L. Z. (2021) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2021.06.011 · Cited by 12
Thajer, A., Baumgartner-Kaut, M., Jorda, A., Hallwirth, U., Lischka, J., & Greber‐Platzer, S. (2022) · Children · doi:10.3390/children9050590 · Cited by 7
Podeanu, M.-A., Vintilescu, Ş. B., Ionele, C. M., Sandu, R. E., Niculescu, C., Florescu, M. M., & Stepan, M. D. (2024) · Life · doi:10.3390/life14091206 · Cited by 7
Kenkre, J. S., Mazaheri, T., Neely, R. D. G., Soran, H., Datta, D. B. N., Penson, P. E., Downie, P., Yates, A. M., Hayden, K., Patel, M., et al. (2025) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632251315303 · Cited by 8
Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy
Teixeira, N., Mourits, M. J. E., Oosterwijk, J. C., Fakkert, I. E., Absalom, A. R., Bakker, S. J. L., van der Meer, P., & de Bock, G. H. (2018) · Familial Cancer · doi:10.1007/s10689-018-0091-5 · Cited by 7
Hallén, J., & Sreeharan, N. (2018) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvy029 · Cited by 7
Targeting triglycerides to lower residual cardiovascular risk
Bubb, K. J., Nelson, A. J., & Nicholls, S. J. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2058489 · Cited by 8
Hypertriglyceridemia, a causal risk factor for atherosclerosis, and its laboratory assessment
Wieczorek, E., Ćwiklińska, A., & Jankowski, M. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0189 · Cited by 7
Association of Serum Apolipoprotein B with the Increased Risk of Diabetes in Korean Men
Lim, H. H., & Kim, O. Y. (2016) · Clinical Nutrition Research · doi:10.7762/cnr.2016.5.3.204 · Cited by 7
Herencia, J. A. C., Rueda, M. S., Bru, A. P., Escribano, F. M., García, I. P., Ródenas, L. M. A., Bernardo, D. C., Divisón, J. A., & Gil-Guillén, V. F. (2018) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2017.10.003 · Cited by 7
Non-HDL as a Valid Surrogate Marker of Small Dense LDL in a Young Indian Population
Manocha, A., Bhargava, S., Jain, R., Kankra, M., Singla, P., & Chugh, P. (2018) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-018-0758-6 · Cited by 6
Guo, C., Yuan, Y., Yue, T., & Li, J. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201800170 · Cited by 7
Colesterol-no HDL como objetivo terapéutico
Brea, Á., Hernández‐Mijares, A., Millán, J., Ascaso, J. F., Blasco, M., Rodríguez, Á. D., Mantilla, T., Pedro‐Botet, J., & Pintó, X. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.07.002 · Cited by 8
Intensive statin therapy for Indians: Part-I. Benefits.
Enas, E. A., Pazhoor, H. C., Kuruvila, A. T., & Vijayaraghavan, K. (2011) · PubMed · Cited by 7
Latest Updates on Lipid Management
Egom, E. E. A., Pharithi, R. B., Hesse, S., Starr, N., Armstrong, R. L., Sulaiman, H. M., Gazdíková, K., Mozos, I. M., Čaprnda, M., Kubatka, P., et al. (2019) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-019-00306-8 · Cited by 5
Kim, C. H., Kim, S. J., Lee, M. J., Kwon, Y. E., Kim, Y. L., Park, K. S., Ryu, H. J., Oh, H. J., Han, S. H., Yoo, T., et al. (2014) · Blood Purification · doi:10.1159/000367803 · Cited by 6
Ke, D., Chen, Q., Wu, Q. F., Li, X., Wu, Z., Li, G., Deng, W., & Mo, X. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.4988 · Cited by 6
Gierach, M., Gierach, J., & Junik, R. (2015) · Endokrynologia Polska · doi:10.5603/ep.a2016.0020 · Cited by 6
Zeng, R., Li, J., Liao, P., & Zhang, M. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.131 · Cited by 6
Herencia, J. A. C., Rueda, M. S., Bru, A. P., Escribano, F. M., García, I. P., Ródenas, L. M. A., Bernardo, D. C., Divisón, J. A., & Gil-Guillén, V. F. (2018) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2017.10.003 · Cited by 8
Lipids: a personal view of the past decade
Katsiki, N., & Mikhailidis, D. P. (2018) · HORMONES · doi:10.1007/s42000-018-0058-9 · Cited by 6
Triglycerides and Cardiovascular Disease : A Scientific Statement From the
Pennathur, S., Kris‐Etherton, P. M., Lennie, T. A., Levi, M., Mazzone, T., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Stone, N. J., Ballantyne, C. M., et al. (2011) · Cited by 6
Loh, W. J., Soh, H. S., Tun, M. H., Tan, P. T., Lau, C. S., Subramaniam, T., Watts, G. F., & Aw, T. C. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1328618 · Cited by 5
Dall, T., & Bays, H. E. (2009) · Southern Medical Journal · doi:10.1097/smj.0b013e31819b08f7 · Cited by 5
Vodnala, D., Bard, R. L., Krishnan, S. M., Jackson, E. A., Rubenfire, M., & Brook, R. D. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.02.004 · Cited by 5
Roman, M. J., Howard, B. V., Howard, W. J., Méte, M., Fleg, J. L., Lee, E. T., & Devereux, R. B. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.172486 · Cited by 5
Cost-effectiveness evaluation of the use of PCSK9 inhibitors
Civeira, F., & Pedro‐Botet, J. (2021) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2021.05.003 · Cited by 5
Bays, H. E. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.10.013 · Cited by 5
Karásek, D., Vaverková, H., Cibičková, Ľ., Gajdová, J., & Kučerová, V. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.01.020 · Cited by 5
Soran, H., Cooper, J. A., Durrington, P. N., Capps, N. E., McDowell, I. F. W., Humphries, S. E., & Neil, A. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000692 · Cited by 5
Opinion paper: Is the Friedewald equation obsolete?
Jialal, I., & Winter, W. E. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.12.032 · Cited by 5
Zhang, L., Qiao, Q., Laatikainen, T. K., Söderberg, S., Jousilahti, P., Onat, A., Nilsson, P. M., & Tuomilehto, J. O. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.12.004 · Cited by 5
Li, Y., Chen, P., & Gao, B. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02820-2 · Cited by 5
Evaluación del coste-efectividad de la utilización de los inhibidores de PCSK9
Civeira, F., & Pedro‐Botet, J. (2021) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2021.05.001 · Cited by 4
Guo, J., Sun, Q., Wu, C., & Wu, J. (2022) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2022.08.017 · Cited by 4
Can the Sasang Constitutional Type Trait Act as an Independent Risk Factor for Dyslipidemia?
Lee, J., Jang, H., Park, B., Lee, E., Koh, B., & Lee, J. (2014) · Journal of Korean Medicine for Obesity Research · doi:10.15429/jkomor.2014.14.2.63 · Cited by 4
Almaghrbi, A., Altarrani, M., Elmighrabi, N., Bakoush, H. M., & Elmabsout, A. A. (2021) · Asian Journal of Basic Science & Research · doi:10.38177/ajbsr.2021.3303 · Cited by 4
Bermúdez, V., Torres, W., Salazar, J. J., Martínez, M. S., Rojas, E., Olivar, L. C., Lameda, V., Ortega, Á., Ramírez, P., Rojas, M., et al. (2018) · F1000Research · doi:10.12688/f1000research.13005.1 · Cited by 4
Guías de práctica clínica de manejo de la dislipemia en diabéticos y otros grupos de riesgo
Fanlo‐Maresma, M., & Pintó, X. (2015) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(15)70118-4 · Cited by 4
Cardiovascular risk and androgenic anabolic steroids
Sculthorpe, N. F., Grace, F., Angell, P. J., Baker, J. S., & George, K. (2012) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2012.7.6.266 · Cited by 4
The impact of the For Heart application on the control of risk factors for cardiovascular diseases
Duchnowski, P., Śmigielski, W., Chałabis, K., Stankiewicz, P., & Łazarczyk, H. (2025) · Kardiologia Polska · doi:10.33963/v.phj.105761 · Cited by 3
Minimizing complications following stent implantation: outcomes and follow-up
Douglas, C. J., & Applegate, R. J. (2013) · Interventional Cardiology · doi:10.2217/ica.13.24 · Cited by 3
Effects of nutrition education on cardio-metabolic outcomes: A randomised clinical trial
Santos, H. D., Beeson, W. L., Segovia‐Siapco, G., Koranda, B., & Jehi, T. (2019) · Health Education Journal · doi:10.1177/0017896919887221 · Cited by 3
Chaparro, M. Á. S., & Fuster, V. P. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.01.003 · Cited by 3
Clinical Effect of Poly Herbal Unani Formulation on Dyslipidemia- A Randomized Trial
Alam, K. M. K., Sheikh, H., & Samad, M. A. (2023) · Turkish Journal of Agriculture - Food Science and Technology · doi:10.24925/turjaf.v11i10.1892-1904.6185 · Cited by 3
Blais, J. E., Akyea, R. K., Coetzee, A., Chan, A. H. Y., Lau, W. C. Y., Man, K. K. C., Harrison, J., Chan, E. W., Beyene, K. A., Wong, I. C. K., et al. (2020) · BJGP Open · doi:10.3399/bjgpopen20x101127 · Cited by 4
Farnier, M. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.37 · Cited by 3
Vrints, C. J., Wood, D., Zamorano, J. L., Zannad, F. M., Karadeniz, Ş., Mezzani, A., Prescott, E., Ebrahim, S. B. J., Germanò, G., Hobbs, R. F., et al. (2013) · Cited by 3
Brinton, E. A., Triscari, J. M., Brudi, P., Chen, E., Johnson‐Levonas, A. O., Sisk, C. M., Ruck, R. A., MacLean, A. A., Maccubbin, D., & Mitchel, Y. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0282-8 · Cited by 3
Genomics and Pharmacogenomics of Lipid-Lowering Therapies
Docherty, K. F., & Padmanabhan, S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386882-4.00031-1 · Cited by 3
Rodríguez, Á. D., Cumplido, A. S., Núñez-Cortés, J. M., de Miguel, M. R., & Peña, M. L. O. (2017) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2017.07.004 · Cited by 3
Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., & Creager, M. A. (2014) · Cited by 2
Bermúdez, V., Torres, W., Salazar, J. J., Martínez, M. S., Rojas, E., Olivar, L. C., Lameda, V., Ortega, Á., Ramírez, P., Rojas, M., et al. (2019) · F1000Research · doi:10.12688/f1000research.13005.2 · Cited by 2
Non-HDL Estimation Methods: Advancing Cardiovascular Disease Prediction
Akbar, A. M., Jha, D., Ali, H., & Ahmad, T. (2023) · Indian Journal of Pharmacy Practice · doi:10.5530/ijopp.16.4.52 · Cited by 2
¿Se están alcanzando las metas en el perfil lipídico de personas con enfermedad coronaria previa?
Merchán, A., Jaramillo, C., Mendoza, F. D. C., & Agudelo, J. F. (2011) · Revista Colombiana de Cardiología · doi:10.1016/s0120-5633(11)70196-6 · Cited by 2
Jacobson, T. A., Jones, P. H., & Roth, E. M. (2010) · Clinical Lipidology · doi:10.2217/clp.10.56 · Cited by 2
Self-citationRoth, E. M., Rosenson, R. S., Jones, P. H., Davidson, M. H., Kelly, M. T., Setze, C. M., Lele, A., & Thakker, K. M. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.02.002 · Cited by 2
Dyslipidemia aterogenna w codziennej praktyce — interdyscyplinarny konsensus polskich ekspertów
Szymański, F. M., Filipiak, K. J., Wożakowska−Kapłon, B., Szaflik, J. P., Dzida, G. J., Kurkowska‐Jastrzębska, I., Narkiewicz, K., Łazicka-Gałecka, M., Gil, R. J., & Gumprecht, J. (2017) · Folia Cardiologica · doi:10.5603/fc.a2016.0106 · Cited by 2
Lipid management in Type 2 diabetes: the case for combination therapy?
Saely, C. H., Drexel, V., Vonbank, A., & Drexel, H. (2011) · Therapy · doi:10.2217/thy.11.5 · Cited by 2
Reiner, Ž. (2010) · Clinical Lipidology · doi:10.2217/clp.10.30 · Cited by 2
Prevención secundaria del ictus isquémico no cardioembólico
Armario, P., Pintó, X., Soler, C., & Cardona, P. (2015) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2015.01.006 · Cited by 2
Perk, J., Backer, G. D., Gohlke, H., Graham, I. M., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cífková, R., et al. (2012) · Ghent University Academic Bibliography (Ghent University) · Cited by 2
Metadata
- Authors
- Robinson, J. G., Wang, S., Smith, B. J., & Jacobson, T. A.
- Affiliations
- University of Iowa (US)
- Emory University (US)
- Corresponding author
- Robinson, Jennifer G.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2009-01
- Volume
- 53
- Issue
- 4
- Pages
- 316-322
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W1996592745
- Cited by
- 368
- References
- 61
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 9 · 2023: 13 · 2022: 16 · 2021: 16 · 2020: 15 · 2019: 24 · 2018: 21 · 2017: 21 · 2016: 30 · 2015: 24 · 2014: 27 · 2013: 31 · 2012: 33
- FWCI
- 5.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Daiichi-Sankyo
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-HDL cholesterol, coronary artery disease, lipid-lowering therapy, statins, fibrates, nicotinic acid, bile acid sequestrants, myocardial infarction, coronary heart disease mortality, relative risk
- MeSH terms
- Clofibric Acid, Coronary Disease, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Niacin, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
